Q-omics provides the consensus-scored VIPR2 profile across patient tissues and cancer cell-line models. VIPR2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, VIPR2 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, VIPR2 RNA expression shows 17,285 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, BLCA, and GBM as cancer lineages where VIPR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VIPR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VIPR2 survival associations across molecular data types. VIPR2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VIPR2 RNA expression–survival associations across cancer types. High VIPR2 expression shows unfavorable associations in LUAD, but favorable associations in HNSC, MESO, UCEC, UVM and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for VIPR2 RNA expression.
This table summarizes VIPR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for VIPR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VIPR2 shows lower tumor expression in BLCA, UCEC, KIRC, LUSC, HNSC and STAD. The BLCA box plot shows higher VIPR2 RNA expression in normal versus tumor tissue (log2 FC = −2.137, t-test p < 0.001).
This table shows molecular features associated with VIPR2 in patient tissues and cancer cell lines. In patient samples, VIPR2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, VIPR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
